Innovative product portfolio
BiOligo has launched a lineup of breakthrough products such as the Super Quenched Probe series, next-generation ARMS-modified primers, ARMS-specific enzymes, UHP-gRNA and UHP-siRNA synthesis. In 2024, we introduced the RQ series probes for IVD, which would enable melting curve analysis solutions to outperform traditional TaqMan probe-based PCR solutions, bringing revolution to the PCR detection field. For gene therapy, we introduced BGP NAM11 transfection reagent, which achieves high transfection efficiency (over 80%) while reducing cellular toxicity by 15%. The company now delivers top-tier, consistent, and reliable raw materials to over 1,000 IVD and CGT (cell & gene therapy) clients worldwide, and is welcoming more partnerships to advance precision diagnosis and treatment for a healthier future.
